Vaccination against SARS-CoV-2: a human enhancement story

Código QR

Vaccination against SARS-CoV-2: a human enhancement story

Abstract Background Vaccination is an essential strategy for mitigating the COVID-19 pandemic. Besides its significance as a public health measure, vaccination is a sophisticated example of modern biotechnology. Since vaccination gives the human body an ability that it does not naturally possess, th...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Niklas Alexander Döbler, Claus-Christian Carbon
Formato:	article
Lenguaje:	EN
Publicado:	BMC 2021
Materias:	Vaccination Human enhancement Ethics Psychology Public Health Policy making Medicine R
Acceso en línea:	https://doaj.org/article/fd717006b6f547daa76a2b8967072a1f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Development of an Inactivated Vaccine against SARS CoV-2
por: Shaikh Terkis Islam Pavel, et al.
Publicado: (2021)

Viral vector-based vaccines against SARS-CoV-2
por: Kenneth Lundstrom
Publicado: (2021)

Sweet Syndrome Following SARS-CoV2 Vaccination
por: Maria Efenesia Baffa, et al.
Publicado: (2021)

Cutaneous Adverse Reactions Associated with SARS-CoV-2 Vaccines
por: Francesco Bellinato, et al.
Publicado: (2021)

Effect of BCG Revaccination on Occupationally Exposed Medical Personnel Vaccinated against SARS-CoV-2
por: Espiridión Ramos-Martinez, et al.
Publicado: (2021)

Efficacy (and safety) of vaccination against SARS-CoV-2 in cancer patients on active treatment
por: Tina Zupančič, et al.
Publicado: (2021)

An Overview of Recent Insights into the Response of TLR to SARS-CoV-2 Infection and the Potential of TLR Agonists as SARS-CoV-2 Vaccine Adjuvants
por: Mohammad Enamul Hoque Kayesh, et al.
Publicado: (2021)

Vaccination against SARS-CoV-2 in Patients with Inflammatory Bowel Diseases: Where Do We Stand?
por: Phil-Robin Tepasse, et al.
Publicado: (2021)

The Barriers, Challenges, and Strategies of COVID-19 (SARS-CoV-2) Vaccine Acceptance: A Concurrent Mixed-Method Study in Tehran City, Iran
por: Hamid Reza Khankeh, et al.
Publicado: (2021)

SARS-CoV-2 immunity and an overview of the COVID-19 vaccines
por: Marković Miloš
Publicado: (2021)

Development of Inactivated FAKHRAVAC<sup>®</sup> Vaccine against SARS-CoV-2 Virus: Preclinical Study in Animal Models
por: Soheil Ghasemi, et al.
Publicado: (2021)

Erythema Multiforme Major following SARS‐CoV‐2 vaccine
por: Alberto Maria Saibene, et al.
Publicado: (2021)

Global Scientific Research on SARS-CoV-2 Vaccines: A Bibliometric Analysis
por: Fakher Rahim, et al.
Publicado: (2021)

Hypersensitivity reaction to hyaluronic acid dermal filler after the Pfizer vaccination against SARS-CoV-2
por: Demetris Savva, et al.
Publicado: (2021)

The vaccination threshold for SARS-CoV-2 depends on the indoor setting and room ventilation
por: A. Mikszewski, et al.
Publicado: (2021)

Predicted Epitope Abundance Supports Vaccine-Induced Cytotoxic Protection Against SARS-CoV-2 Variants of Concern
por: Antonio J. Martín-Galiano, et al.
Publicado: (2021)

Impact of scaling up SARS-CoV-2 vaccination on COVID-19 hospitalizations in Spain
por: Ignacio Barandalla, et al.
Publicado: (2021)

Cross-reactive antibodies after SARS-CoV-2 infection and vaccination
por: Marloes Grobben, et al.
Publicado: (2021)

Use of Quantitative Dried Blood Spots to Evaluate the Post-Vaccination Level of Neutralizing Antibodies against SARS-CoV-2
por: Alexandre Marchand, et al.
Publicado: (2021)

Considering Frailty in SARS-CoV-2 Vaccine Development: How Geriatricians Can Assist
por: Andrew MK, et al.
Publicado: (2021)

Antibody Titer Kinetics and SARS-CoV-2 Infections Six Months after Administration with the BNT162b2 Vaccine
por: Davide Ferrari, et al.
Publicado: (2021)

Recombinant protein subunit SARS-CoV-2 vaccines formulated with CoVaccine HT™ adjuvant induce broad, Th1 biased, humoral and cellular immune responses in mice
por: Chih-Yun Lai, et al.
Publicado: (2021)

First Report of Two Cases of Löfgren’s Syndrome after SARS-CoV-2 Vaccination-Coincidence or Causality?
por: Jan-Gerd Rademacher, et al.
Publicado: (2021)

A pathogen-like antigen-based vaccine confers immune protection against SARS-CoV-2 in non-human primates
por: Chang Guo, et al.
Publicado: (2021)

The Pfizer-BNT162b2 mRNA-based vaccine against SARS-CoV-2 may be responsible for awakening the latency of herpes varicella-zoster virus
por: M.D. Maldonado, et al.
Publicado: (2021)

Thromboembolic and hemorrhagic risks after vaccination against SARS-CoV-2: a systematic review and meta-analysis of randomized controlled trials
por: Noppacharn Uaprasert, et al.
Publicado: (2021)

SARS-CoV-2 spike protein: Site-specific breakpoints for the development of COVID-19 vaccines
por: Palaniyandi Velusamy, et al.
Publicado: (2021)

The Bacterial Mucosal Immunotherapy MV130 Protects Against SARS-CoV-2 Infection and Improves COVID-19 Vaccines Immunogenicity
por: Carlos del Fresno, et al.
Publicado: (2021)

Intranasal Delivery of MVA Vector Vaccine Induces Effective Pulmonary Immunity Against SARS-CoV-2 in Rodents
por: Berislav Bošnjak, et al.
Publicado: (2021)

CoV-RBD121-NP Vaccine Candidate Protects against Symptomatic Disease following SARS-CoV-2 Challenge in K18-hACE2 Mice and Induces Protective Responses That Prevent COVID-19-Associated Immunopathology
por: Jennifer K. DeMarco, et al.
Publicado: (2021)

Oral Bacteria Combined with an Intranasal Vaccine Protect from Influenza A Virus and SARS-CoV-2 Infection
por: Minami Nagai, et al.
Publicado: (2021)

Immune Evasive Effects of SARS-CoV-2 Variants to COVID-19 Emergency Used Vaccines
por: Yandi Zhang, et al.
Publicado: (2021)

Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine
por: Felipe Melo-González, et al.
Publicado: (2021)

A Chimeric Japanese Encephalitis Vaccine Protects against Lethal Yellow Fever Virus Infection without Inducing Neutralizing Antibodies
por: Niraj Mishra, et al.
Publicado: (2020)

Impaired Functional T-Cell Response to SARS-CoV-2 After Two Doses of BNT162b2 mRNA Vaccine in Older People
por: Julie Demaret, et al.
Publicado: (2021)

The protective immunity induced by SARS-CoV-2 infection and vaccination: a critical appraisal
por: Eduardo Tosta
Publicado: (2021)

Clusters of SARS-CoV-2 Lineage B.1.1.7 Infection after Vaccination with Adenovirus-Vectored and Inactivated Vaccines
por: William M. de Souza, et al.
Publicado: (2021)

Anti-Spike SARS-CoV-2 IgG Assessment with a Commercial Assay during a 4-Month Course after COVID-19 Vaccination
por: Jakub Swadźba, et al.
Publicado: (2021)

High Individual Heterogeneity of Neutralizing Activities against the Original Strain and Nine Different Variants of SARS-CoV-2
por: Rita Jaafar, et al.
Publicado: (2021)

Sulphated polysaccharides from seaweeds as potential entry inhibitors and vaccine adjuvants against SARS-CoV-2 RBD spike protein: a computational approach
por: Mountasser Douma, et al.
Publicado: (2021)